Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duodenal Eubacterium hallii infusion in men with metabolic syndrome
NL-OMON23717Recruiting
- Sponsor
- Amsterdam UMC
- Start
- Dec 2017
- Countries
- 1
01
Overview
Randomised, double-blind trial in cardiometabolic risk (CMR) (2 arms), sponsored by Amsterdam UMC. Primary endpoints: Change in duodenal Eubacterium hallii levels and Change in small intestinal gene expression. Started Dec 2017; status: recruiting.
02
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON23717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23717.